Serum levels of interleukins 2, 6 and 8, soluble interteuktn-2 receptor and intercellular adhesion molecule 7 during treatment with interleukin-2 plus interferon-alfa

Immunopharmacology and Immunotoxicology

Volumn 18, Issue 3, 1996, Pages 337-354

  Vuoristo, Meri Sisko ^a,b   Kellokumpu Lehtinen, Pirkko ^a,b   Laine, Seppo ^a   Soppi, Esa ^c  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c Pharmacia Ltd   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; MELANOMA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029790678     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.3109/08923979609052740     Document Type: Article

References (33)

1. Smith, K.A., Interleukin-2: inception, impact, and implications, Science, 240:1169, 1988.
2. Knop, J., Immunologic effects of interferon, J. Invest. Dermatol., 95:72S, 1990.
3. Blay, J.-Y., Negrier, S., Combaret, V., Attali, S., Goulot E., Merrouche, Y., Mercatello, A., Ravault, A., Tourani, J.-M., Moskovtchenko, J.-F., Philip, T., Favrot, M., Serum level of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma, Cancer Res., 52:3317, 1992.
4. Jablons, D.M., Mule, J.J., McIntosh, J.K., Seghal, P.B., May, L.T., Huang, C.M., Rosenberg, S.A., Lotze, M.T., IL-6/IFN-6-2 as a circulating hormone, J. Immunol., 142:1542, 1989.
5. Tabibzadeh, S.S., Poubouridis, D., May, L.T., Seghal, P.B., Interleukin-6 immunoreactivity in human tumors, Am. J. Pathol., 135:427, 1989.
6. Wang, J.M., Taraboletti, G., Matsushima, K., Van Damme, J., Mantovani, A., Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8, Biochem. Biophys. Res. Commun., 169:165, 1990.
7. Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Ettinghausen, S.E., Matory, Y.L., Skibber, J.M., Shiloni, E., Vetto, J.T., Seipp, C.A., Simpson, C., Reichert, C.M., Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N. Engl. J. Med., 313:1485, 1985.
8. Rubin, L.A., Nelson, D.L., The soluble interleukin-2 receptor: biology, function and clinical application, Ann. Intern. Med., 113:619, 1990.
9. Østenstad, B., Soluble interleukin-2 receptor levels in patients with malignant melanoma and renal cell cancer, Acta Oncol., 31:413, 1992.
10. Rovelli, F., Lissoni, P., Crispino, S., Barni, S., Fumagalli, G., Paolorossi, F., Tancini, G., Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study, Tumori, 74:633, 1988.
11. Larson, R.S., Springer, T.A., Structure and function of leukocyte integrins, Immunol. Rev., 114:181, 1990.
12. Rothlein, R., Mainolfi, E.A., Czajkowski, M., Marlin, S.D., A form of circulating ICAM-1 in human serum, J. Immunol., 147:3788, 1991.
13. Banks, R.E., Gearing, A.J.H., Hemingway, I.K., Norfolk, D.R., Perren, T.J., Selby, P.J., Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies, Br. J. Cancer, 68:122, 1993.
14. Gruss, H.J., Dölken, G., Brach, M.A., Mertelsmann, R., Herrmann, F., Serum levels of circulating ICAM-1 are increased in Hodgkin's disease, Leukemia, 7:1245, 1993.
15. Harning, R., Mainolfi, E., Bysiryn, J.-C., Henn, M., Merluzzi, V.J., Rothlein, R., Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma, Cancer Res., 51:5003, 1991.
16. Levin, I., Klein, T., Shapira, Y., Lurie, H., Kfir, B., Narinsky, R., Lehmann, J.M., Klein, B., Serum intracellular adhesion molecule 1 (sICAM-1) and soluble HLA class 1 antigens in breast cancer patients in relation to tumor burden, Oncology Rep., 1:217, 1994.
17. Becker, J.C., Dummer, R., Schwinn, A., Hartmann, A.A., Burg, G., Circulating intercellular adhesion molecule-1 in melanoma patients: induction by interleukin-2 therapy, J. Immunother., 12:147, 1992.
18. Lindemann, A., Brossart, P., Höffken, K., Flasshove, M., Voliotis, D., Diehl, V., Kulmburg, P., Wagner, H., Mertelsmann, R.,. Serum cytokine levels in cancer patients treated with different schedules of ultra-low-dose interleukin-2, J. Immunother., 15:225, 1994.
19. Lissoni, P., Tisi, E., Brivio, F., Barni, S., Rovelli, F., Perego, M., Tancini, G., Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2, Eur. J. Cancer, 27:1014, 1991.
20. Lotze, M.T., Custer, M.C., Sharrow, S.O., Rubin, L.A., Nelson, D.L., Rosenberg, S.A., In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2-receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration, Cancer Res., 47:2188, 1987.
21. McIntyre, C.A., Chapman, K., Reeder, S., Dorreen, M.S., Bruce, L., Rodgers, S., Hayat, K., Schreenivasan, T., Sheridan, E., Hancock, B.W., Rees, R.C.,. Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants. Eur. J. Cancer, 28:58, 1992.
22. Tilg, H., Shapiro, I., Atkins, M.B., Dinarello, C.A., Mier, J.W., Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera, J. Immunol., 151:3299, 1993.
23. Tartour, E., Dorval, T., Mosseri, V., Deneux, L., Mathiot, C., Brailly, H., Montero, F., Joyeux, I., Pouiltart, P., Fridman, W.H., Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients, Br. J. Cancer, 69:911, 1994.
24. Vuoristo, M.-S., Jantunen, I., Pyrhönen, S., Muhonen, T., Kellokumpu-Lehtinen, P., A combination of subcutaneous recombinant interleukin-2 and recombinant alfa interferon in the treatment of advanced renal cell carcinoma or melanoma, Eur. J. Cancer, 30A:530, 1994.
25. Atzpodien, J., Körfer, A., Franks, C.R., Poliwoda, H., Kirchner, H., Home therapy with recombinant interleukin-2 and interferon-alfa-2b in advanced human malignancies. Lancet, 335:1509, 1990.
26. Hayat, K., Rodgers, S., Bruce, L., Rees, R.C., Chapman, K., Reeder, S., Dorreen, M.S., Sheridan, E., Sreenivasan, T., Hancock, B.W., Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2, Eur. J. Cancer, 27:1009, 1991.
27. Lissoni, P., Barni, S., Ardizzoia, A., Crispino, S., Paolorossi, F., Archili, C., VaghL, M., Tancini, G., Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha, Eur. J. Cancer, 28:92, 1992.
28. Lotze, M.T., Matory, Y.L., Rayner, A.A., Ettinghausen, S.E., Vetto, J.T., Seipp, C.A., Rosengerg, S.A., Clinical effects and toxicity of interleukin-2 in patients with cancer, Cancer 58:2764, 1986.
29. Kageshita T., Yoshii A., Kimura T., Kuriya, N., Ono, T., Tsujisaki, M., Imai, K., Ferrone, S., Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma, Cancer Res., 53:4927, 1993.
30. Becker, J.C., Dummer, R., Hartmann, A.A., Burg, G., Schmidt, R.E., Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alfa, J. Immunol., 147:4398, 1991.
31. Zeller, W., Fiedler, W., Peimann, C.-J., Schäfer, B., Hossfeld, O.K., Shedding of TNF-receptor and soluble ICAM-1 molecules in response to treatment with recombinant TNF-alfa and IFN-gamma in patients with colorectal cancer, Oncology Rep., 1:13, 1994.
32. Zachariae, C.O.C., Thestrup-Pedersen, K., Matsushima, K., Expression and secretion of leucocyte chemotactic cytokines by normal human melanocytes and melanoma cells, J. Invest. Dermatol., 97:593, 1991.
33. Schadendorf, D., Möller, A., Algermissen, B., Worm, M., Sticherling, M., Czarnetzki, B.M., IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor, J. Immunol., 151:2667, 1993.